Literature DB >> 2543664

Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors.

F Oyama1, S Hirohashi, Y Shimosato, K Titani, K Sekiguchi.   

Abstract

Alternative splicing of fibronectin pre-mRNA at the ED-A region has been shown to be regulated in a tissue- and developmental stage-specific manner. We investigated the splicing pattern at this region in malignant and nonmalignant human liver tissues and found that the relative population of the fibronectin mRNA containing the ED-A sequence is markedly increased in malignant liver tumors. Nontumorous liver tissues including those with chronic hepatitis and cirrhosis did not show any significant change in the alternative splicing at the ED-A region. It was also found that the increased expression of the ED-A-containing fibronectin mRNA closely correlates with the occurrence of portal vein tumor thrombus and intrahepatic metastasis, which are two characteristic features of invasive liver tumors. These results indicate that tissue-specific alternative splicing of fibronectin mRNA is modified in human liver cancer and raise a possibility that the putative molecular machinery governing alternative RNA splicing of not only fibronectin but also other cellular proteins is deregulated in malignant human tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543664

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  HRS/SRp40-mediated inclusion of the fibronectin EIIIB exon, a possible cause of increased EIIIB expression in proliferating liver.

Authors:  K Du; Y Peng; L E Greenbaum; B A Haber; R Taub
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

2.  Biosynthesis and secretion of mucin-related products in Hs746T gastric cancer cells.

Authors:  S Sano; K Okazaki; Y Yamamoto
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

3.  Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.

Authors:  Lu Zhang; Xiaoqiao Liu; Xuegong Zhang; Ronghua Chen
Journal:  Mol Genet Genomics       Date:  2015-12-28       Impact factor: 3.291

Review 4.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

5.  Fibronectin expression in the normal and hypertrophic rat heart.

Authors:  W S Mamuya; P Brecher
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 6.  Extracellular matrix-mediated cellular communication in the heart.

Authors:  Iñigo Valiente-Alandi; Allison E Schafer; Burns C Blaxall
Journal:  J Mol Cell Cardiol       Date:  2016-01-14       Impact factor: 5.000

7.  Involvement of large tenascin-C splice variants in breast cancer progression.

Authors:  Takatsugu Tsunoda; Hiroyasu Inada; Ilunga Kalembeyi; Kyoko Imanaka-Yoshida; Mirei Sakakibara; Ray Okada; Koji Katsuta; Teruyo Sakakura; Yuichi Majima; Toshimichi Yoshida
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

8.  Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin.

Authors:  Sophie Astrof; Denise Crowley; Richard O Hynes
Journal:  Dev Biol       Date:  2007-07-12       Impact factor: 3.582

9.  Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.

Authors:  Sophie Astrof; Denise Crowley; Elizabeth L George; Tomohiko Fukuda; Kiyotoshi Sekiguchi; Douglas Hanahan; Richard O Hynes
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Aging-associated changes in renal extracellular matrix.

Authors:  C K Abrass; M J Adcox; G J Raugi
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.